Patents
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
07/2004
07/07/2004CN1511146A Preparation of taxus alkane derivative
07/07/2004CN1511143A Herbicidal substituted benzoylpyrazoles
07/07/2004CN1511034A Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
07/07/2004CN1156452C Compound as anti-inflammatory agent
07/06/2004US6759538 Substituted diphenyl heterocycles useful for treating HCV infection
07/06/2004US6759425 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
07/06/2004US6759420 Low molecular weight, factor xa specific blood clotting inhibitors without side effects
07/06/2004US6759419 Pyrrolidinone derivatives, their preparation and pharmaceutical composition comprising the same
07/06/2004US6759411 Heterocyclic piperidines as modulators of chemokine receptor activity
07/06/2004US6759409 Inhibitors of papilloma virus
07/06/2004CA2119556C Substituted aryl- and heteroaryl-phenyloxazolidinones
07/06/2004CA2105822C Herbicidal 4-heteroaroylisoxazole derivatives
07/06/2004CA2085201C New pyridyl derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
07/01/2004WO2004055015A1 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
07/01/2004WO2004055012A1 Indane compounds as ccr5 antagonists
07/01/2004WO2004055011A1 Heterocyclic compounds as ccr5 antagonists
07/01/2004WO2004055010A2 Cyclopropyl compounds as ccr5 antagonists
07/01/2004WO2004055007A1 3-substituted-4-pyrimidone derivatives
07/01/2004WO2004054999A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
07/01/2004WO2004054987A1 Cathepsin cysteine protease inhibitors and their use
07/01/2004WO2004054984A1 4-substituted benzimidazoles and their use as inhibitors of gastric secretion
07/01/2004WO2004054624A1 Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
07/01/2004WO2004054581A2 Cyclohexyl compounds as ccr5 antagonists
07/01/2004WO2004026306A3 Pyrazole derivatives as transforming growth factor (tgf) inhibitors
07/01/2004WO2004017911A3 Protease inhibitors
07/01/2004WO2004012656A3 Thiophene and furan derivatives as prostaglandin agonists and use thereof
07/01/2004WO2003096984A3 Drug therapy for celiac sprue
07/01/2004WO2003093297A3 Protein kinase modulators and methods of use
07/01/2004US20040127733 adrenergic blocking agents; for treatment of diabetes/obesity
07/01/2004US20040127708 antiviral activities; aids treatment
07/01/2004US20040127707 Novel phthalazinones
07/01/2004US20040127536 Indazole Derivatives
07/01/2004US20040127530 treating gram-negative microbial infections
07/01/2004US20040127527 Large conductance calcium-activated k channel opener
07/01/2004US20040127515 For therapy of hypertension, chronic obstructive pulmonary disease, organ damage, pain, diabetic nephropathy, dementia
07/01/2004US20040127502 Use of pyrimidine compound galanin receptor subtype 3 (GAL3) antagonists, which may be classified as neutral antagonists, inverse agonists or allosteric modulators, to treat depressive disorders and/or anxiety
07/01/2004US20040127497 Pyridyl substituted heterocycles useful for treating or preventing HCV infection
07/01/2004US20040127494 Sulfur compounds such as (2R)-2-[N-(4-Chlorobenzenesulfonyl)-N-(4-methoxybenzyl)amino]-4-methylpentanoic acid amide, used for prophylaxis of neurodegenarative disorders such as Alzheimer's Disease and Down's Syndrome
07/01/2004US20040127492 Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2
07/01/2004US20040127426 Peptidic compounds as cysteine protease inhibitors
07/01/2004US20040127382 activity of peroxy compounds in washing, bleaching and cleaning processes at low temperature is increased by the transition metal complexes
07/01/2004US20040123948 Adjust adhesion at interface of microelectronics packages; shrinkage inhibition
07/01/2004DE10259933A1 Substituierte 4-Aryl-Pyridine 4-aryl-substituted pyridines
07/01/2004DE10259407A1 New bicyclic nitrogen-containing heteroaryl-substituted amides, are inhibitors of Factor Xa and/or related serine proteases, useful as antithrombotic agents, e.g. for treating or preventing deep leg vein thrombosis
07/01/2004CA2549463A1 Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
07/01/2004CA2509244A1 Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
07/01/2004CA2508838A1 4-substituted benzimidazoles and their use as inhibitors of gastric secretion
07/01/2004CA2507629A1 Enantiomers of thiophene hydroxamic acid derivatives and their use as hdac inhibitors
06/2004
06/30/2004EP1433788A1 Pyrazole-derivatives as factor Xa inhibitors
06/30/2004EP1433786A1 Benzoxazole compound and pharmaceutical composition containing the compound
06/30/2004EP1433783A2 Naphthalenecarboxamides as tachykinin receptor antagonists
06/30/2004EP1432706A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
06/30/2004EP1432705A2 Dual action antibiotics
06/30/2004EP1432701A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract
06/30/2004EP1432698A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
06/30/2004EP1432696A1 Chroman derivatives as 5-hydroxytryptamine-6 ligands
06/30/2004EP1432694A1 Stereospecific process for the synthesis of 2-yl chroman derivatives
06/30/2004EP1432693A2 Mch receptor antagonists
06/30/2004EP1432691A1 Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
06/30/2004EP1432690A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
06/30/2004EP1432689A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders
06/30/2004EP1432687A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
06/30/2004EP1432420A2 Benzimidazolidinone derivatives as muscarinic agents
06/30/2004EP1432417A2 Substituted benzimidazole compounds and their use for the treatment of cancer
06/30/2004EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
06/30/2004EP1432313A1 N-thio-nicotinamide derivatives and related compounds for use as pesticides
06/30/2004EP1080081B1 Benzofuroxan derivatives and their use in treating angina pectoris
06/30/2004CN1509281A Benzimidazol derivatives modulate che mokine receptors
06/30/2004CN1509278A N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound
06/30/2004CN1509275A Metalloproteinase inhibitors
06/30/2004CN1509274A Metallo proteinase inhibitors
06/30/2004CN1509273A Metalloproteinase inhibitors
06/30/2004CN1509173A Carboxylic and substituted oxazole derivatives for use as PPAR-& and PPAR-r activators in the treatment of diabetes
06/30/2004CN1155596C New phenylpiperazines
06/30/2004CN1155590C Chromone compounds with antineoplastic activity and its open-loop products and preparing process
06/29/2004US6756406 Antiarthritic agents; rheumatic diseases; osteoarthritis; inhibition of the inducible nitric oxide synthase - induced after activation of vascular smooth muscle, macrophages, endothelial cells by enotoxin and cytokines
06/29/2004US6756378 VLA-4 inhibitor compounds
06/29/2004US6756372 For therapy of autoimmune diseases, alzheimer's disease, atherosclerosis, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, crohn's disease, ulcerative colitis, multiple sclerosis, guillain-barre syndrome, psoriasis
06/29/2004US6756370 Piperidine alcohols
06/29/2004US6756367 Useful in the treatment of any state with increased endogenous level of corticotropin releasing hormone(crf) or hpa (hypothalamic pituitary axis) is disregulated or diseases induced by crf, including inflammatory disorders, anxiety etc
06/29/2004CA2207404C Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
06/29/2004CA2205384C Dihydropyrimidines and uses thereof
06/29/2004CA2171827C Use of thiazolidinediones to prevent or delay onset of niddm
06/24/2004WO2004052887A2 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
06/24/2004WO2004052886A1 Indol derivatives and their use as 5-ht ligands
06/24/2004WO2004052880A1 Pyridine derivatives as jnk inhibitors and their use
06/24/2004WO2004052871A1 Benzomorpholine derivatives
06/24/2004WO2004052869A1 5-substituted-pyrazine or pyridine glucokinase activators
06/24/2004WO2004052868A1 Pyrazine-based tubulin inhibitors
06/24/2004WO2004052864A1 Pyrazole and imidazole compounds and uses thereof
06/24/2004WO2004052861A1 Hydroxyalkylated cyclic diamine compound
06/24/2004WO2004052852A1 3-pyrrolyl urea derivatives and their use as antiviral agents
06/24/2004WO2004052851A1 Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
06/24/2004WO2004052373A1 Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
06/24/2004WO2004052372A1 Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction
06/24/2004WO2004052366A1 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
06/24/2004WO2004052280A2 Anti-angiogenic compounds and their use in cancer treatment
06/24/2004WO2004037807A3 Medicinal arylethanolamine compounds
06/24/2004WO2004019869A3 Indoles having anti-diabetic activity
06/24/2004WO2004018044A8 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent